Child's Nervous System

, Volume 32, Issue 1, pp 9–11 | Cite as

Excellent response to levetiracetam in epilepsy with Wolf-Hirschhorn syndrome

  • Zeynep Selen Karalok
  • Ebru Petek Arhan
  • Kadri Murat Erdogan
  • Esra Gurkas
Letter to the Editor

Dear Editor:

Wolf-Hirschhorn syndrome (WHS) is a rare genetic disorder caused by subtelomeric deletion of a segment of the short arm (p) of chromosome 4. Epilepsy constitutes a major medical challenge especially during the first years of life and occurs in 50–100 % of patients with WHS The conventional antiepileptic drugs such as carbamazepine, phenobarbitale, and valproic acid have been tried and are rarely effective in these patients [1, 2]. Levetiracetam is a new line antiepileptic drug indicated for partial seizures with or without secondary generalization.

We would like to share a case experience of WHS successfully treated by levetiracetam. A 12-month-old female infant was referred to our hospital for ongoing fever-induced seizures and developmental delay. She had been delivered by cesarean section at 33 weeks, with a birth weight of 1625 g. She was the second child of healthy, nonconsanguineous parents, with no family history of note. She had intrauterine growth retardation....


Intellectual Disability Levetiracetam Translocation Carrier Phenobarbitale Treatment Conventional Anticonvulsant Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with ethical standards

Conflict of interest

The authors declare that thay have no conflict of interest.


  1. 1.
    Zollino M, Murdolo M, Marangi G, Pecile V, Galasso C, Mazzanti L, Neri G (2008) On the nosology and pathogenesis of Wolf-Hirschhorn syndrome: genotype-phenotype correlation analysis of 80 patients and literature review. Am J Med Genet 148:257–269CrossRefGoogle Scholar
  2. 2.
    Battaglia D, Zampino G, Zollino M et al (2003) Electroclinical patterns and evolution of epilepsy in the 4p- syndrome. Epilepsia 44:1183–1190CrossRefPubMedGoogle Scholar
  3. 3.
    Sheth F, Akinde OR, Datar C, Adeteye OV, Sheth J (2012) Genotype-phenotype characterization of Wolf-Hirschhom syndrome confirmed by FISH: case reports. Case Rep Genet 2012:878796PubMedCentralPubMedGoogle Scholar
  4. 4.
    Battaglia A, Filippi T, South ST, Carey JC (2009) Spectrum of epilepsy and electroencephalogram patterns in Wolf–Hirschhorn syndrome: experience with 87 patients. Dev Med Child Neurol 51:373–380CrossRefPubMedGoogle Scholar
  5. 5.
    Nagarkatti N, Deshpande LS, DeLorenzo RJ (2009) Development of the calcium plateau following status epilepticus: role of calcium in epileptogenesis. Expert Rev Neurother 9:813–824PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Klitgaard H, Pitkanen A (2003) Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord 5:9–16Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Zeynep Selen Karalok
    • 1
  • Ebru Petek Arhan
    • 2
  • Kadri Murat Erdogan
    • 3
  • Esra Gurkas
    • 1
  1. 1.Department of Pediatric NeurologyAnkara Pediatric & Pediatric Hematology Oncology Training and Research HospitalDıskapı/AnkaraTurkey
  2. 2.Department of Pediatric NeurologyGazi University Faculty of MedicineAnkaraTurkey
  3. 3.Ankara Etlik Zübeyde Hanım Maternity and Women’s Health Research and Training HospitalAnkaraTurkey

Personalised recommendations